Research statistics

Vasoactive Intestinal Peptide (VIP) research: publications and trials

What has been published on Vasoactive Intestinal Peptide (VIP): PubMed publications, the kind of evidence they report and registered clinical trials. These are counts of research, not a judgment of whether Vasoactive Intestinal Peptide (VIP) works or is safe. For what it is and what the studies found, see the Vasoactive Intestinal Peptide (VIP) profile.
Automated weekly refresh · data through November 15, 2026

At a glance

Publications, all years

7,193

Since 1971

Publications in 2026 so far

39

Through November 15, 2026

Human clinical research

12.2%

865 of 7,107 classified

Registered clinical trials

15

ClinicalTrials.gov

Randomized controlled trials

46

Publications reporting an RCT in people

Systematic reviews and meta-analyses

3

Preclinical studies

81.8%

4,736 animal · 1,060 in vitro · 17 computational

Records that only mention it

7,088

Not counted above

Status in the library: Research only. 86 publications are not yet classified by study type.

What to keep in mind

  • More than 70% of the indexed publications are animal, cell or computational studies.
  • Some completed trials have neither posted results nor a linked results publication.
  • The body makes this molecule itself, so much of its literature is physiology rather than research on it as a compound.

Publications by year

Vasoactive Intestinal Peptide (VIP) publications by year and evidence

1971, Preclinical (animal, in vitro, computational): 1 of 11972, Preclinical (animal, in vitro, computational): 1 of 11973, Human clinical research: 1 of 61973, Preclinical (animal, in vitro, computational): 3 of 61973, Other and not yet classified: 2 of 61974, Preclinical (animal, in vitro, computational): 3 of 41974, Reviews and meta-analyses: 1 of 41975, Human clinical research: 2 of 71975, Preclinical (animal, in vitro, computational): 1 of 71975, Reviews and meta-analyses: 1 of 71975, Other and not yet classified: 3 of 71976, Human clinical research: 5 of 231976, Preclinical (animal, in vitro, computational): 14 of 231976, Other and not yet classified: 4 of 231977, Human clinical research: 11 of 421977, Preclinical (animal, in vitro, computational): 28 of 421977, Other and not yet classified: 3 of 421978, Human clinical research: 15 of 641978, Preclinical (animal, in vitro, computational): 45 of 641978, Other and not yet classified: 4 of 641979, Human clinical research: 13 of 641979, Preclinical (animal, in vitro, computational): 46 of 641979, Reviews and meta-analyses: 2 of 641979, Other and not yet classified: 3 of 641980, Human clinical research: 18 of 1141980, Preclinical (animal, in vitro, computational): 90 of 1141980, Reviews and meta-analyses: 4 of 1141980, Other and not yet classified: 2 of 1141981, Human clinical research: 15 of 911981, Preclinical (animal, in vitro, computational): 72 of 911981, Reviews and meta-analyses: 2 of 911981, Other and not yet classified: 2 of 911982, Human clinical research: 14 of 1061982, Preclinical (animal, in vitro, computational): 83 of 1061982, Reviews and meta-analyses: 2 of 1061982, Other and not yet classified: 7 of 1061983, Human clinical research: 26 of 1851983, Preclinical (animal, in vitro, computational): 146 of 1851983, Reviews and meta-analyses: 4 of 1851983, Other and not yet classified: 9 of 1851984, Human clinical research: 33 of 2041984, Preclinical (animal, in vitro, computational): 165 of 2041984, Reviews and meta-analyses: 5 of 2041984, Other and not yet classified: 1 of 2041985, Human clinical research: 21 of 2321985, Preclinical (animal, in vitro, computational): 204 of 2321985, Reviews and meta-analyses: 3 of 2321985, Other and not yet classified: 4 of 2321986, Human clinical research: 24 of 2501986, Preclinical (animal, in vitro, computational): 215 of 2501986, Reviews and meta-analyses: 10 of 2501986, Other and not yet classified: 1 of 2501987, Human clinical research: 29 of 2411987, Preclinical (animal, in vitro, computational): 203 of 2411987, Reviews and meta-analyses: 3 of 2411987, Other and not yet classified: 6 of 2411988, Human clinical research: 29 of 3181988, Preclinical (animal, in vitro, computational): 250 of 3181988, Reviews and meta-analyses: 30 of 3181988, Other and not yet classified: 9 of 3181989, Human clinical research: 24 of 2881989, Preclinical (animal, in vitro, computational): 252 of 2881989, Reviews and meta-analyses: 8 of 2881989, Other and not yet classified: 4 of 2881990, Human clinical research: 26 of 2681990, Preclinical (animal, in vitro, computational): 232 of 2681990, Reviews and meta-analyses: 6 of 2681990, Other and not yet classified: 4 of 2681991, Human clinical research: 23 of 2581991, Preclinical (animal, in vitro, computational): 223 of 2581991, Reviews and meta-analyses: 8 of 2581991, Other and not yet classified: 4 of 2581992, Human clinical research: 27 of 2611992, Preclinical (animal, in vitro, computational): 229 of 2611992, Reviews and meta-analyses: 1 of 2611992, Other and not yet classified: 4 of 2611993, Human clinical research: 29 of 2691993, Preclinical (animal, in vitro, computational): 231 of 2691993, Reviews and meta-analyses: 7 of 2691993, Other and not yet classified: 2 of 2691994, Human clinical research: 20 of 2781994, Preclinical (animal, in vitro, computational): 247 of 2781994, Reviews and meta-analyses: 4 of 2781994, Other and not yet classified: 7 of 2781995, Human clinical research: 25 of 2501995, Preclinical (animal, in vitro, computational): 209 of 2501995, Reviews and meta-analyses: 13 of 2501995, Other and not yet classified: 3 of 2501996, Human clinical research: 26 of 2771996, Preclinical (animal, in vitro, computational): 230 of 2771996, Reviews and meta-analyses: 18 of 2771996, Other and not yet classified: 3 of 2771997, Human clinical research: 19 of 1981997, Preclinical (animal, in vitro, computational): 174 of 1981997, Reviews and meta-analyses: 4 of 1981997, Other and not yet classified: 1 of 1981998, Human clinical research: 18 of 2261998, Preclinical (animal, in vitro, computational): 194 of 2261998, Reviews and meta-analyses: 11 of 2261998, Other and not yet classified: 3 of 2261999, Human clinical research: 15 of 1661999, Preclinical (animal, in vitro, computational): 138 of 1661999, Reviews and meta-analyses: 11 of 1661999, Other and not yet classified: 2 of 1662000, Human clinical research: 19 of 1842000, Preclinical (animal, in vitro, computational): 155 of 1842000, Reviews and meta-analyses: 8 of 1842000, Other and not yet classified: 2 of 1842001, Human clinical research: 12 of 1482001, Preclinical (animal, in vitro, computational): 126 of 1482001, Reviews and meta-analyses: 9 of 1482001, Other and not yet classified: 1 of 1482002, Human clinical research: 18 of 1422002, Preclinical (animal, in vitro, computational): 113 of 1422002, Reviews and meta-analyses: 9 of 1422002, Other and not yet classified: 2 of 1422003, Human clinical research: 11 of 1552003, Preclinical (animal, in vitro, computational): 131 of 1552003, Reviews and meta-analyses: 13 of 1552004, Human clinical research: 14 of 1262004, Preclinical (animal, in vitro, computational): 99 of 1262004, Reviews and meta-analyses: 12 of 1262004, Other and not yet classified: 1 of 1262005, Human clinical research: 12 of 1162005, Preclinical (animal, in vitro, computational): 92 of 1162005, Reviews and meta-analyses: 12 of 1162006, Human clinical research: 10 of 1422006, Preclinical (animal, in vitro, computational): 120 of 1422006, Reviews and meta-analyses: 11 of 1422006, Other and not yet classified: 1 of 1422007, Human clinical research: 14 of 1372007, Preclinical (animal, in vitro, computational): 99 of 1372007, Reviews and meta-analyses: 19 of 1372007, Other and not yet classified: 5 of 1372008, Human clinical research: 14 of 1162008, Preclinical (animal, in vitro, computational): 85 of 1162008, Reviews and meta-analyses: 14 of 1162008, Other and not yet classified: 3 of 1162009, Human clinical research: 13 of 902009, Preclinical (animal, in vitro, computational): 73 of 902009, Reviews and meta-analyses: 4 of 902010, Human clinical research: 18 of 1032010, Preclinical (animal, in vitro, computational): 77 of 1032010, Reviews and meta-analyses: 8 of 1032011, Human clinical research: 11 of 862011, Preclinical (animal, in vitro, computational): 62 of 862011, Reviews and meta-analyses: 12 of 862011, Other and not yet classified: 1 of 862012, Human clinical research: 13 of 792012, Preclinical (animal, in vitro, computational): 52 of 792012, Reviews and meta-analyses: 12 of 792012, Other and not yet classified: 2 of 792013, Human clinical research: 16 of 882013, Preclinical (animal, in vitro, computational): 64 of 882013, Reviews and meta-analyses: 5 of 882013, Other and not yet classified: 3 of 882014, Human clinical research: 13 of 852014, Preclinical (animal, in vitro, computational): 64 of 852014, Reviews and meta-analyses: 6 of 852014, Other and not yet classified: 2 of 852015, Human clinical research: 12 of 612015, Preclinical (animal, in vitro, computational): 44 of 612015, Reviews and meta-analyses: 5 of 612016, Human clinical research: 13 of 602016, Preclinical (animal, in vitro, computational): 41 of 602016, Reviews and meta-analyses: 6 of 602017, Human clinical research: 7 of 452017, Preclinical (animal, in vitro, computational): 35 of 452017, Reviews and meta-analyses: 2 of 452017, Other and not yet classified: 1 of 452018, Human clinical research: 17 of 732018, Preclinical (animal, in vitro, computational): 49 of 732018, Reviews and meta-analyses: 6 of 732018, Other and not yet classified: 1 of 732019, Human clinical research: 13 of 652019, Preclinical (animal, in vitro, computational): 45 of 652019, Reviews and meta-analyses: 7 of 652020, Human clinical research: 13 of 592020, Preclinical (animal, in vitro, computational): 41 of 592020, Reviews and meta-analyses: 5 of 592021, Human clinical research: 18 of 642021, Preclinical (animal, in vitro, computational): 36 of 642021, Reviews and meta-analyses: 8 of 642021, Other and not yet classified: 2 of 642022, Human clinical research: 12 of 672022, Preclinical (animal, in vitro, computational): 45 of 672022, Reviews and meta-analyses: 9 of 672022, Other and not yet classified: 1 of 672023, Human clinical research: 13 of 612023, Preclinical (animal, in vitro, computational): 38 of 612023, Reviews and meta-analyses: 7 of 612023, Other and not yet classified: 3 of 612024, Human clinical research: 10 of 482024, Preclinical (animal, in vitro, computational): 35 of 482024, Reviews and meta-analyses: 2 of 482024, Other and not yet classified: 1 of 482025, Human clinical research: 11 of 622025, Preclinical (animal, in vitro, computational): 39 of 622025, Reviews and meta-analyses: 6 of 622025, Other and not yet classified: 6 of 622026 (to date), Human clinical research: 10 of 392026 (to date), Preclinical (animal, in vitro, computational): 24 of 392026 (to date), Reviews and meta-analyses: 3 of 392026 (to date), Other and not yet classified: 2 of 39Human clinical researchPreclinical (animal, in vitro, computational)Reviews and meta-analysesOther and not yet classified010020030040019711983199520072026*
Counted PubMed publications by year of first publication. * 2026 runs to November 15, 2026. A larger bar is more publications, not stronger evidence.
Show the data
YearHuman clinical researchPreclinical (animal, in vitro, computational)Reviews and meta-analysesOther and not yet classifiedTotal
197101001
197201001
197313026
197403104
197521137
19765140423
197711280342
197815450464
197913462364
1980189042114
198115722291
1982148327106
19832614649185
19843316551204
19852120434232
198624215101250
19872920336241
198829250309318
19892425284288
19902623264268
19912322384258
19922722914261
19932923172269
19942024747278
199525209133250
199626230183277
19971917441198
199818194113226
199915138112166
20001915582184
20011212691148
20021811392142
200311131130155
20041499121126
20051292120116
200610120111142
20071499195137
20081485143116
200913734090
2010187780103
2011116212186
2012135212279
201316645388
201413646285
201512445061
201613416060
20177352145
201817496173
201913457065
202013415059
202118368264
202212459167
202313387361
202410352148
202511396662
2026 (to date)10243239

Study types

Animal study4,736
In vitro study1,060
Observational human study401
Review375
Case report222
Other clinical trial196
Not yet classified86
Editorial, letter or other51
Randomized controlled trial46
Computational study17
Systematic review3

Research areas

From MeSH major topics. A paper can be in several areas.

Gastrointestinal1,921
Neurological and mental health1,837
Endocrinology1,347
Immune system892
Cardiovascular766
Oncology703
Reproductive and sexual health441
Musculoskeletal413
Metabolic health274
Tissue repair180
Antimicrobial and infectious disease164
Dermatology155

Registered clinical trials

1 of 7 trials completed at least a year before the cutoff have neither posted results nor a linked results publication. A registration is not a result.

Completed: 10 · Terminated: 2 · Active, not recruiting: 1 · No longer available: 1 · Withdrawn: 1
Phase not applicable: 6 · Phase 1: 1 · Phase 2: 3 · Phase 2 / Phase 3: 2 · Phase 3: 3

TrialStatusPhaseStartedResults
Inhaled ZYESAMI (Aviptadil Acetate) for Treatment of Severe COVID-19NCT05137795WithdrawnPhase 32021-12—
Inhaled Aviptadil for the Treatment of COVID-19 in Patients at High Risk for ARDSNCT04536350 · 83 enrolledTerminatedPhase 22021-05—
ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19NCT04843761 · 473 enrolledCompletedPhase 32021-04Posted
Aviptadil for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)NCT06729606 · 471 enrolledCompletedPhase 32021-04Posted
A Clinical Study Evaluating Inhaled Aviptadil on COVID-19NCT04844580 · 80 enrolledCompletedPhase 22021-03—
Inhaled ZYESAMI™ (Aviptadil Acetate) for the Treatment of Severe COVID-19NCT04360096 · 144 enrolledTerminatedPhase 2, Phase 32021-02—
I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill PatientsNCT04488081 · 1,500 enrolledActive, not recruitingPhase 22020-07—
The Effects of a Long-lasting Infusion of Vasoactive Intestinal Peptide (VIP) in Episodic Migraine PatientsNCT04260035 · 21 enrolledCompletedPhase not applicable2020-05—
Intravenous Aviptadil for Critical COVID-19 With Respiratory FailureNCT04311697 · 203 enrolledCompletedPhase 2, Phase 32020-05Posted
The Effects of a Long-lasting Infusion of Vasoactive Intestinal Peptide (VIP) on Headache, Cranial Hemodynamic and Autonomic Symptoms in Healthy VolunteersNCT03989817 · 12 enrolledCompletedPhase not applicable2019-06—
Effect of PACAP38/VIP on Migraineurs Measured by Magnetic ResonanceNCT01471990 · 24 enrolledCompletedPhase not applicable2011-05—
Hemodynamic and Headache-Inducing Effect of Intravenous Vasoactive Intestinal Peptide in MigraineursNCT00272896 · 12 enrolledCompletedPhase not applicable2004-10—
Vasoactive Intestinal Peptide in COPDNCT00464932 · 34 enrolledCompletedPhase not applicable2003-06—
Phase I Study of Vasoactive Intestinal Peptide in Patients With Acute Respiratory Distress Syndrome and SepsisNCT00004494 · 18 enrolledCompletedPhase 11998-09—
ZYESAMI (Aviptadil) Intermediate Population Expanded Access Protocol (SAMICARE)NCT04453839No longer availablePhase not applicable——

Human trials and evidence reviews

Meta-analyses, systematic reviews and trials in people, newest first.

  1. Vasoactive intestinal Peptide as a diagnostic or prognostic biomarker in multiple sclerosis: A systematic review.

    Multiple sclerosis and related disorders · July 5, 2026 · Systematic review · cited 0 times · open access

    PMID 42447728 · DOI 10.1016/j.msard.2026.107377 · Reviews and meta-analyses

  2. Retinal VIP-amacrine cells: their development, structure, and function.

    Eye (London, England) · December 8, 2023 · Systematic review · cited 9 times · open access

    PMID 38066110 · DOI 10.1038/s41433-023-02844-x · Reviews and meta-analyses

  3. Clinicopathological data and treatment modalities for pancreatic vipomas: a systematic review.

    Journal of B.U.ON. : official journal of the Balkan Union of Oncology · March 1, 2019 · Systematic review · cited 24 times

    PMID 31127985 · Reviews and meta-analyses

  4. Inhaled Aviptadil Is a New Hope for Recovery of Lung Damage due to COVID-19.

    Medical principles and practice : international journal of the Kuwait University, Health Science Centre · January 27, 2025 · Randomized controlled trial · cited 7 times · open access

    PMID 39870064 · DOI 10.1159/000543773 · Human clinical research

  5. Hemostatic mechanism of Jianpi Yiqi Shexue decoction in treatment of immune thrombocytopenia.

    Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · June 1, 2024 · Randomized controlled trial · cited 1 times · open access

    PMID 38767638 · DOI 10.19852/j.cnki.jtcm.20240423.003 · Human clinical research

  6. Intravenous aviptadil and remdesivir for treatment of COVID-19-associated hypoxaemic respiratory failure in the USA (TESICO): a randomised, placebo-controlled trial.

    The Lancet. Respiratory medicine · June 19, 2023 · Randomized controlled trial · cited 19 times · open access

    PMID 37348524 · DOI 10.1016/s2213-2600(23)00147-9 · Human clinical research

  7. The Use of IV Vasoactive Intestinal Peptide (Aviptadil) in Patients With Critical COVID-19 Respiratory Failure: Results of a 60-Day Randomized Controlled Trial.

    Critical care medicine · August 29, 2022 · Randomized controlled trial · cited 28 times · open access

    PMID 36044317 · DOI 10.1097/ccm.0000000000005660 · Human clinical research

  8. PACAP38- and VIP-induced cluster headache attacks are not associated with changes of plasma CGRP or markers of mast cell activation.

    Cephalalgia : an international journal of headache · November 25, 2021 · Randomized controlled trial · cited 27 times

    PMID 34822741 · DOI 10.1177/03331024211056248 · Human clinical research

  9. Effect of Vasoactive Intestinal Polypeptide on Development of Migraine Headaches: A Randomized Clinical Trial.

    JAMA network open · August 2, 2021 · Randomized controlled trial · cited 81 times · open access

    PMID 34357396 · DOI 10.1001/jamanetworkopen.2021.18543 · Human clinical research

  10. The effect of pituitary adenylate cyclase-activating peptide-38 and vasoactive intestinal peptide in cluster headache.

    Cephalalgia : an international journal of headache · September 22, 2020 · Randomized controlled trial · cited 35 times

    PMID 32962406 · DOI 10.1177/0333102420940689 · Human clinical research

Most cited

By OpenAlex citation count. Citations measure attention, not quality or correctness.

  1. Type 2 innate lymphoid cells control eosinophil homeostasis.

    Nature · September 15, 2013 · Animal study · cited 1,068 times · open access

    PMID 24037376 · DOI 10.1038/nature12526 · Animal studies

  2. International Union of Pharmacology. XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide.

    Pharmacological reviews · June 1, 1998 · Review · cited 765 times · open access

    PMID 9647867 · Reviews and meta-analyses

  3. Vasoactive intestinal polypeptide mediates circadian rhythmicity and synchrony in mammalian clock neurons.

    Nature neuroscience · March 6, 2005 · Animal study · cited 764 times · open access

    PMID 15750589 · DOI 10.1038/nn1419 · Animal studies

  4. Functional expression and tissue distribution of a novel receptor for vasoactive intestinal polypeptide.

    Neuron · April 1, 1992 · Animal study · cited 745 times

    PMID 1314625 · DOI 10.1016/0896-6273(92)90101-i · Animal studies

  5. Neuronal cell killing by the envelope protein of HIV and its prevention by vasoactive intestinal peptide.

    Nature · October 1, 1988 · Animal study · cited 608 times

    PMID 2845276 · DOI 10.1038/335639a0 · Animal studies

Latest publications

  1. VIP-Mediated Syndromes: Contrasting Presentations and Multidisciplinary Management of Two Rare Neuroendocrine Tumors.

    ACG case reports journal · October 28, 2026 · Case report · cited 0 times · open access

    PMID 42953880 · DOI 10.14309/crj.0000000000002382 · Human clinical research

  2. Programmable Engineered Living Vehicles as Autonomous Biofactories for Synergistic Osteomyelitis Management and Bone Regeneration.

    Advanced materials (Deerfield Beach, Fla.) · October 26, 2026 · Animal study · cited 0 times

    PMID 42929733 · DOI 10.1002/adma.75118 · Animal studies

  3. Living Donor Liver Transplantation for Vasoactive Intestinal Peptide-Secreting Tumors with Watery Diarrhea, Hypokalemia, and Achlorhydria Syndrome Resulting from Transformation of a Nonfunctional Pancreatic Neuroendocrine Tumor with Multiple Liver Metastases: A Case Report.

    Surgical case reports · October 10, 2026 · Case report · cited 0 times · open access

    PMID 42889871 · DOI 10.70352/scrj.cr.26-0465 · Human clinical research

  4. Composite pheochromocytoma-ganglioneuroma secreting vasoactive intestinal peptide.

    Endocrinology, diabetes & metabolism case reports · October 1, 2026 · Case report · cited 0 times · open access

    PMID 42825457 · DOI 10.1530/edm-25-0184 · Human clinical research

  5. Influence of exogenous glucagon-like peptide 2 on mechanisms of enteric neurotransmitter-mediated vasorelaxation in the isolated bovine mesenteric artery and vein.

    Physiological reports · October 1, 2026 · Animal study · cited 0 times · open access

    PMID 42855814 · DOI 10.14814/phy2.71134 · Animal studies

  6. Serum VIP and IL-1β Levels Are Associated With Anxiety and Depression in Patients With Parkinson's Disease: A Cross-Sectional Study.

    Brain and behavior · September 1, 2026 · Observational human study · cited 0 times · open access

    PMID 42677804 · DOI 10.1002/brb3.71742 · Human clinical research

  7. Intranasal delivery of a vasoactive intestinal peptide-based circRNA vaccine induces systemic and mucosal immunity against RSV in mice.

    Molecular therapy : the journal of the American Society of Gene Therapy · August 19, 2026 · Animal study · cited 0 times

    PMID 42619264 · DOI 10.1016/j.ymthe.2026.08.025 · Animal studies

  8. VIPoma Presenting With Obstructive Jaundice: A Case Report.

    Journal of the ASEAN Federation of Endocrine Societies · August 6, 2026 · Case report · cited 0 times · open access

    PMID 42802744 · DOI 10.15605/jafes.041.02.6165 · Human clinical research

  9. Effects of Biling Weitong granules on gastrointestinal motility and gastrointestinal hormones levels in rats with functional dyspepsia.

    Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · August 1, 2026 · Animal study · cited 0 times · open access

    PMID 42639771 · DOI 10.19852/j.cnki.jtcm.2026.04.007 · Animal studies

  10. HSV-1 Infection Differentially Modulates NPY and VIP Neuropeptide Expression in the Mouse Brain and in Human Neuronal Cells.

    International journal of molecular sciences · July 28, 2026 · Animal study · cited 0 times · open access

    PMID 42589390 · DOI 10.3390/ijms27156735 · Animal studies

Browse all 7,193 publications in the dashboard

How this is counted

PubMed records matched by the names below, counted when the peptide is in the title, indexed by MeSH, or confirmed from the abstract. The exact query can be rerun on Europe PMC. Methodology

Search terms: Aviptadil; Vasoactive Intestinal Peptide

((TITLE_ABS:"Aviptadil" OR CHEM:"Aviptadil") OR (TITLE_ABS:"Vasoactive Intestinal Peptide" OR CHEM:"Vasoactive Intestinal Peptide")) AND SRC:MED

Cite this page

Peptide Library. (2026, November 16). Vasoactive Intestinal Peptide (VIP) research statistics (Version weekly-2026-11-15) [Statistic]. Peptide Library. https://peptidelibrary.app/research/peptides/vip